Abstract:Abstract Background Classical swine fever (CSF) is one of the most devastating pig diseases that affect the swine industry worldwide. Besides stamping out policy for eradication, immunization with vaccines of live attenuated CSF or the CSF-E2 subunit is an efficacious measure of disease control. However, after decades of efforts, it is still hard to eliminate CSF from endemically affected regions and reemerging areas. Most of previous studies demonstrated the efficacy of different CSF vaccines in laboratories under high containment conditions, which may not represent the practical performance in field farms. The inadequate vaccine efficacy induced by unrestrained factors may lead to chronic or persistent CSF infection in animals that develop a major source for virus shedding among pig populations. In this study, a vaccination-challenge-cohabitation trial on specific-pathogen-free (SPF) pigs and long-term monitoring of conventional sows and their offspring were used to evaluate the efficacy and the impact of maternally derived antibody (MDA) interference on CSF vaccines in farm applications. Results The trials demonstrated higher neutralizing antibody (NA) titers with no clinical symptoms and significant pathological changes in the CSF-E2 subunit vaccine immunized group after CSFV challenge. Additionally, none of the sentinel pigs were infected during cohabitation indicating that the CSF-E2 subunit vaccine could provoke adequately acquired immunity to prevent horizontal transmission. In field farm applications, sows immunized with CSF-E2 subunit vaccine revealed an average of higher and consistent antibody level with significant reduction of CSF viral RNA detection via saliva monitoring in contrast to those of live attenuated CSF vaccine immunized sows possessing diverse antibody titer distributions and higher viral loads. Furthermore, early application of the CSF-E2 subunit vaccine in 3-week-old piglets illustrated no MDA interference on primary immunization and could elicit consistent and long-lasting adequate antibody response suggesting the flexibility of CSF-E2 subunit vaccine on vaccination program determination. Conclusions The CSF-E2 subunit vaccine demonstrated significant efficacy and no MDA interference for immunization in both pregnant sows and piglets. These advantages provide a novel approach to avoid possible virus shedding in sow population and MDA interference in piglets for control of CSF in field farm applications.

Identification of E2 Strain with Improved Secretion and Immunogenicity Against CSFV in Piglets

Enhanced protective immunity to CSFV E2 subunit vaccine by using IFN-γ as immunoadjuvant in weaning piglets.

Safety, efficacy, and DIVA feasibility on a novel live attenuated classical swine fever marker vaccine candidate

Evaluation of classical swine fever E2 (CSF-E2) subunit vaccine efficacy in the prevention of virus transmission and its potential application for virus eradication in field farms

Evaluation of classical swine fever E2 (CSF-E2) subunit vaccine efficacy in the prevention of virus transmission and impact of maternal derived antibody interference in field farm applications

Pigs Immunized with A Novel E2 Subunit Vaccine Are Protected from Subgenotype Heterologous Classical Swine Fever Virus Challenge

Generation and Efficacy Evaluation of Recombinant Classical Swine Fever Virus E2 Glycoprotein Expressed in Stable Transgenic Mammalian Cell Line

Construction of a Chimeric Classical Swine Fever Virus C-strain Containing E2 of Group Ⅱ Isolate Remains and Its Biological Characteristics

Expression of E2 Protein of Classical Swine Fever Virus Shimen Strain Using Baculovrius Expression System

Efficient Mucosal Vaccination of a Novel Classical Swine Fever Virus E2-Fc Fusion Protein Mediated by Neonatal Fc Receptor.

Candidate peptide-vaccines induced immunity against CSFV and identified sequential neutralizing determinants in antigenic domain A of glycoprotein E2.

Recombinant Swinepox Virus Expressing Glycoprotein E2 of Classical Swine Fever Virus Confers Complete Protection in Pigs Upon Viral Challenge

Commercial E2 Subunit Vaccine Provides Full Protection to Pigs Against Lethal Challenge with 4 Strains of Classical Swine Fever Virus Genotype 2.

Glycoprotein E2 of Classical Swine Fever Virus Expressed by Baculovirus Induces the Protective Immune Responses in Rabbits

Self-Assembling Nanovaccine Enhances Protective Efficacy Against CSFV in Pigs

Analysis of cross-reactivity of different E2 proteins with antisera of subgroup 2 field isolates and vaccine C-strain of classic swine fever virus

Prokaryotic Expression and Immunogenicity of E2 Gene of CSFV Guizhou Epidemic Strain

Toward the Development of a One-Dose Classical Swine Fever Subunit Vaccine: Antigen Titration, Immunity Onset, and Duration of Immunity

Efficacy Evaluation of the C-strain-based Vaccines Against the Subgenotype 2.1d Classical Swine Fever Virus Emerging in China

The swine CD81 enhances E2-based DNA vaccination against classical swine fever

Baculovirus Surface Display of E2 Envelope Glycoprotein of Classical Swine Fever Virus and Immunogenicity of the Displayed Proteins in A Mouse Model